A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

The purpose of this study is to evaluate the efficacy of Pumitamig versus Pembrolizumab in participants with previously untreated advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%.

Trial Details

NCT ID
NCT07361510
Phase
PHASE3
Sponsor
Bristol-Myers Squibb
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Pumitamig
  • Pembrolizumab
Locations (sample)
  • Daphne, Alabama, United States|30.60353,-87.9036
  • Bullhead City, Arizona, United States|35.14778,-114.5683
  • Glendale, Arizona, United States|33.53865,-112.18599
  • Anaheim, California, United States|33.83529,-117.9145
  • Beverly Hills, California, United States|34.07362,-118.40036

Key Eligibility Criteria

  • Participants must have a histologically or cytologically confirmed diagnosis of Non-Small Cell Lung Cancer (NSCLC) (squamous and nonsquamous) with …
  • Participants must have a programmed death ligand-1 (PD-L1) expression ≥ 50%.
  • Participants must have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
  • Participants must have no prior systemic anti-tumor therapy for locally advanced or metastatic NSCLC.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →